Survodutide: Boehringer's Dual Glucagon/GLP-1 Drug

A New Approach: Adding Glucagon to GLP-1

Most people know glucagon as the hormone that raises blood sugar — the opposite of insulin. At first glance, activating the glucagon receptor in a weight loss drug seems counterintuitive. But glucagon does much more than regulate blood sugar, and its metabolic effects are proving to be a powerful complement to GLP-1 therapy.

Glucagon receptor activation increases energy expenditure by stimulating thermogenesis (heat production) in tissues. It promotes liver fat oxidation, directly burning the fat stored in liver cells. It reduces hepatic lipogenesis, stopping the liver from making new fat. And it suppresses appetite through central nervous system pathways distinct from GLP-1.

By combining these glucagon effects with GLP-1's proven appetite suppression, insulin enhancement, and gastric slowing, survodutide creates a metabolic profile that is uniquely suited to addressing obesity and its most dangerous complication: fatty liver disease.

Clinical Trial Data

The Energy Expenditure Advantage

One criticism of GLP-1-only medications is that weight loss occurs primarily through reduced caloric intake without increasing energy expenditure. In fact, GLP-1 medications may slightly reduce resting metabolic rate as body weight decreases (a natural adaptation to weight loss). Survodutide's glucagon component may partially counteract this metabolic adaptation.

By stimulating thermogenesis, glucagon receptor activation increases the number of calories your body burns at rest. While the magnitude of this effect in survodutide has not been precisely quantified in large trials, preclinical data and early clinical signals suggest it is meaningful enough to contribute to the larger weight loss observed compared to GLP-1-only approaches.

This has implications for weight maintenance as well. A medication that maintains energy expenditure during weight loss could theoretically reduce the likelihood of weight plateau and make long-term weight maintenance easier. Learn more about how different mechanisms affect weight loss outcomes.

Side Effects and Safety Considerations

Survodutide's side effect profile includes expected GLP-1 class effects plus some considerations related to the glucagon component:

• GI effects: Nausea, vomiting, and diarrhea are the most common, consistent with other GLP-1 medications. Slow dose titration helps manage these.
• Heart rate increase: Glucagon receptor agonism may modestly increase heart rate. This was observed in trials and is being monitored closely in Phase 3 studies.
• Blood sugar balance: While the glucagon component could theoretically raise blood sugar, the GLP-1 component effectively counterbalances this. Net glycemic control was improved in trials.
• Appetite effects: Some patients experience more profound appetite suppression than with GLP-1 alone, requiring attention to adequate nutritional intake.

Who Could Benefit Most from Survodutide?

Based on its unique mechanism, survodutide may be particularly well-suited for specific patient populations:

• Patients with fatty liver disease: The glucagon-driven liver fat reduction makes survodutide potentially the best GLP-1-class option for patients with NAFLD/MASH.
• Patients who plateau on GLP-1-only medications: The energy expenditure boost from glucagon activation may help overcome weight loss plateaus.
• Patients with elevated liver enzymes: Those whose ALT and AST elevations are driven by fatty liver may see particularly dramatic improvements.
• Patients seeking maximal weight loss without surgery: The approximately 19% weight loss in Phase 2 trials places survodutide among the most effective medications in development.

Frequently Asked Questions